Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380

1.

Cancer stem-cell marker CD44v9-positive cells arise from Helicobacter pylori-infected CAPZA1-overexpressing cells.

Tsugawa H, Kato C, Mori H, Matsuzaki J, Kameyama K, Saya H, Hatakeyama M, Suematsu M, Suzuki H.

Cell Mol Gastroenterol Hepatol. 2019 May 27. pii: S2352-345X(19)30070-0. doi: 10.1016/j.jcmgh.2019.05.008. [Epub ahead of print]

2.

Visualization of spatiotemporal dynamics of human glioma stem cell invasion.

Tamura R, Miyoshi H, Sampetrean O, Shinozaki M, Morimoto Y, Iwasawa C, Fukaya R, Mine Y, Masuda H, Maruyama T, Narita M, Saya H, Yoshida K, Okano H, Toda M.

Mol Brain. 2019 May 6;12(1):45. doi: 10.1186/s13041-019-0462-3.

3.

ROCK Inhibition Induces Terminal Adipocyte Differentiation and Suppresses Tumorigenesis in Chemoresistant Osteosarcoma Cells.

Takahashi N, Nobusue H, Shimizu T, Sugihara E, Yamaguchi-Iwai S, Onishi N, Kunitomi H, Kuroda T, Saya H.

Cancer Res. 2019 Jun 15;79(12):3088-3099. doi: 10.1158/0008-5472.CAN-18-2693. Epub 2019 Apr 16.

PMID:
30992323
4.

Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension.

Isobe S, Kataoka M, Endo J, Moriyama H, Okazaki S, Tsuchihashi K, Katsumata Y, Yamamoto T, Shirakawa K, Yoshida N, Shimoda M, Chiba T, Masuko T, Hakamata Y, Kobayashi E, Saya H, Fukuda K, Sano M.

Am J Respir Cell Mol Biol. 2019 Mar 21. doi: 10.1165/rcmb.2018-0231OC. [Epub ahead of print]

PMID:
30897333
5.

Glucose transporter 1-mediated vascular translocation of nanomedicines enhances accumulation and efficacy in solid tumors.

Suzuki K, Miura Y, Mochida Y, Miyazaki T, Toh K, Anraku Y, Melo V, Liu X, Ishii T, Nagano O, Saya H, Cabral H, Kataoka K.

J Control Release. 2019 May 10;301:28-41. doi: 10.1016/j.jconrel.2019.02.021. Epub 2019 Mar 4.

PMID:
30844476
6.

Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.

Ogihara K, Kikuchi E, Okazaki S, Hagiwara M, Takeda T, Matsumoto K, Kosaka T, Mikami S, Saya H, Oya M.

Cancer Sci. 2019 Apr;110(4):1431-1441. doi: 10.1111/cas.13960. Epub 2019 Mar 1.

7.

An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.

Motohara T, Masuda K, Morotti M, Zheng Y, El-Sahhar S, Chong KY, Wietek N, Alsaadi A, Karaminejadranjbar M, Hu Z, Artibani M, Gonzalez LS, Katabuchi H, Saya H, Ahmed AA.

Oncogene. 2019 Apr;38(16):2885-2898. doi: 10.1038/s41388-018-0637-x. Epub 2018 Dec 19. Review.

PMID:
30568223
8.

Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.

Miyoshi S, Tsugawa H, Matsuzaki J, Hirata K, Mori H, Saya H, Kanai T, Suzuki H.

Anticancer Res. 2018 Nov;38(11):6163-6170. doi: 10.21873/anticanres.12969.

PMID:
30396933
9.

T-type Calcium Channels Determine the Vulnerability of Dopaminergic Neurons to Mitochondrial Stress in Familial Parkinson Disease.

Tabata Y, Imaizumi Y, Sugawara M, Andoh-Noda T, Banno S, Chai M, Sone T, Yamazaki K, Ito M, Tsukahara K, Saya H, Hattori N, Kohyama J, Okano H.

Stem Cell Reports. 2018 Nov 13;11(5):1171-1184. doi: 10.1016/j.stemcr.2018.09.006. Epub 2018 Oct 18.

10.

Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells.

Okazaki S, Shintani S, Hirata Y, Suina K, Semba T, Yamasaki J, Umene K, Ishikawa M, Saya H, Nagano O.

Oncotarget. 2018 Sep 18;9(73):33832-33843. doi: 10.18632/oncotarget.26112. eCollection 2018 Sep 18.

11.

Therapeutic potential of tranilast for the treatment of chronic graft-versus-host disease in mice.

Mukai S, Ogawa Y, Saya H, Kawakami Y, Tsubota K.

PLoS One. 2018 Oct 11;13(10):e0203742. doi: 10.1371/journal.pone.0203742. eCollection 2018.

12.

Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.

Suina K, Tsuchihashi K, Yamasaki J, Kamenori S, Shintani S, Hirata Y, Okazaki S, Sampetrean O, Baba E, Akashi K, Mitsuishi Y, Takahashi F, Takahashi K, Saya H, Nagano O.

Cancer Sci. 2018 Dec;109(12):3874-3882. doi: 10.1111/cas.13826. Epub 2018 Nov 5.

13.

Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent.

Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, Hadano S, Aoki M, Saya H, Sobue G, Okano H.

Nat Med. 2018 Oct;24(10):1579-1589. doi: 10.1038/s41591-018-0140-5. Epub 2018 Aug 20.

PMID:
30127392
14.

HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer.

Hosonaga M, Arima Y, Sampetrean O, Komura D, Koya I, Sasaki T, Sato E, Okano H, Kudoh J, Ishikawa S, Saya H, Ishikawa T.

Int J Mol Sci. 2018 Jul 24;19(8). pii: E2158. doi: 10.3390/ijms19082158.

15.

Gold-nanofève surface-enhanced Raman spectroscopy visualizes hypotaurine as a robust anti-oxidant consumed in cancer survival.

Shiota M, Naya M, Yamamoto T, Hishiki T, Tani T, Takahashi H, Kubo A, Koike D, Itoh M, Ohmura M, Kabe Y, Sugiura Y, Hiraoka N, Morikawa T, Takubo K, Suina K, Nagashima H, Sampetrean O, Nagano O, Saya H, Yamazoe S, Watanabe H, Suematsu M.

Nat Commun. 2018 Apr 19;9(1):1561. doi: 10.1038/s41467-018-03899-1.

16.

Tranilast inhibits the expression of genes related to epithelial-mesenchymal transition and angiogenesis in neurofibromin-deficient cells.

Harigai R, Sakai S, Nobusue H, Hirose C, Sampetrean O, Minami N, Hata Y, Kasama T, Hirose T, Takenouchi T, Kosaki K, Kishi K, Saya H, Arima Y.

Sci Rep. 2018 Apr 17;8(1):6069. doi: 10.1038/s41598-018-24484-y.

17.

Periostin antisense oligonucleotide suppresses bleomycin-induced formation of a lung premetastatic niche for melanoma.

Semba T, Sugihara E, Kamoshita N, Ueno S, Fukuda K, Yoshino M, Takao K, Yoshikawa K, Izuhara K, Arima Y, Suzuki M, Saya H.

Cancer Sci. 2018 May;109(5):1447-1454. doi: 10.1111/cas.13554. Epub 2018 Mar 31.

18.

Recurrent Spindle Cell Carcinoma Shows Features of Mesenchymal Stem Cells.

Ouchi T, Morikawa S, Shibata S, Takahashi M, Yoshikawa M, Soma T, Miyashita H, Muraoka W, Kameyama K, Kawana H, Arima Y, Saya H, Okano H, Nakagawa T, Asoda S.

J Dent Res. 2018 Jul;97(7):779-786. doi: 10.1177/0022034518759278. Epub 2018 Mar 1.

PMID:
29494307
19.

Development of a functional thyroid model based on an organoid culture system.

Saito Y, Onishi N, Takami H, Seishima R, Inoue H, Hirata Y, Kameyama K, Tsuchihashi K, Sugihara E, Uchino S, Ito K, Kawakubo H, Takeuchi H, Kitagawa Y, Saya H, Nagano O.

Biochem Biophys Res Commun. 2018 Mar 4;497(2):783-789. doi: 10.1016/j.bbrc.2018.02.154. Epub 2018 Feb 19.

PMID:
29470983
20.

Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.

Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT.

Oncotarget. 2018 Jan 4;9(6):6872-6882. doi: 10.18632/oncotarget.23914. eCollection 2018 Jan 23.

21.

CD44 variant inhibits insulin secretion in pancreatic β cells by attenuating LAT1-mediated amino acid uptake.

Kobayashi N, Okazaki S, Sampetrean O, Irie J, Itoh H, Saya H.

Sci Rep. 2018 Feb 12;8(1):2785. doi: 10.1038/s41598-018-20973-2.

22.

Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.

Hagiwara M, Kikuchi E, Tanaka N, Kosaka T, Mikami S, Saya H, Oya M.

BMC Cancer. 2018 Jan 31;18(1):113. doi: 10.1186/s12885-018-3988-3.

23.

Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality.

Kitagawa M, Liao PJ, Lee KH, Wong J, Shang SC, Minami N, Sampetrean O, Saya H, Lingyun D, Prabhu N, Diam GK, Sobota R, Larsson A, Nordlund P, McCormick F, Ghosh S, Epstein DM, Dymock BW, Lee SH.

Nat Commun. 2017 Dec 19;8(1):2200. doi: 10.1038/s41467-017-02287-5.

24.

CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.

Kawano Y, Iwama E, Tsuchihashi K, Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Lung Cancer. 2017 Nov;113:72-78. doi: 10.1016/j.lungcan.2017.09.008. Epub 2017 Sep 14.

PMID:
29110853
25.

Establishment of pten knockout medaka with transcription activator-like effector nucleases (TALENs) as a model of PTEN deficiency disease.

Matsuzaki Y, Sakuma T, Yamamoto T, Saya H.

PLoS One. 2017 Oct 20;12(10):e0186878. doi: 10.1371/journal.pone.0186878. eCollection 2017.

26.

Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model.

Shibao S, Minami N, Koike N, Fukui N, Yoshida K, Saya H, Sampetrean O.

Neuro Oncol. 2018 Feb 19;20(3):343-354. doi: 10.1093/neuonc/nox170.

27.

Organotypic brain explant culture as a drug evaluation system for malignant brain tumors.

Minami N, Maeda Y, Shibao S, Arima Y, Ohka F, Kondo Y, Maruyama K, Kusuhara M, Sasayama T, Kohmura E, Saya H, Sampetrean O.

Cancer Med. 2017 Nov;6(11):2635-2645. doi: 10.1002/cam4.1174. Epub 2017 Oct 4.

28.

Prospects for new lung cancer treatments that target EMT signaling.

Otsuki Y, Saya H, Arima Y.

Dev Dyn. 2018 Mar;247(3):462-472. doi: 10.1002/dvdy.24596. Epub 2017 Oct 25. Review.

29.

Convection-enhanced delivery of sulfasalazine prolongs survival in a glioma stem cell brain tumor model.

Haryu S, Saito R, Jia W, Shoji T, Mano Y, Sato A, Kanamori M, Sonoda Y, Sampetrean O, Saya H, Tominaga T.

J Neurooncol. 2018 Jan;136(1):23-31. doi: 10.1007/s11060-017-2621-7. Epub 2017 Sep 19.

PMID:
28929335
30.

Stat3 as a potential therapeutic target for rheumatoid arthritis.

Oike T, Sato Y, Kobayashi T, Miyamoto K, Nakamura S, Kaneko Y, Kobayashi S, Harato K, Saya H, Matsumoto M, Nakamura M, Niki Y, Miyamoto T.

Sci Rep. 2017 Sep 8;7(1):10965. doi: 10.1038/s41598-017-11233-w.

31.

Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma.

Nishino M, Ozaki M, Hegab AE, Hamamoto J, Kagawa S, Arai D, Yasuda H, Naoki K, Soejima K, Saya H, Betsuyaku T.

J Cancer. 2017 Jul 1;8(10):1774-1785. doi: 10.7150/jca.19732. eCollection 2017.

32.

Reducing Inflammatory Cytokine Production from Renal Collecting Duct Cells by Inhibiting GATA2 Ameliorates Acute Kidney Injury.

Yu L, Moriguchi T, Kaneko H, Hayashi M, Hasegawa A, Nezu M, Saya H, Yamamoto M, Shimizu R.

Mol Cell Biol. 2017 Oct 27;37(22). pii: e00211-17. doi: 10.1128/MCB.00211-17. Print 2017 Nov 15.

33.

Modeling phenotypes of malignant gliomas.

Sampetrean O, Saya H.

Cancer Sci. 2018 Jan;109(1):6-14. doi: 10.1111/cas.13351. Epub 2017 Nov 15. Review.

34.

Endothelium-induced three-dimensional invasion of heterogeneous glioma initiating cells in a microfluidic coculture platform.

Chonan Y, Taki S, Sampetrean O, Saya H, Sudo R.

Integr Biol (Camb). 2017 Sep 18;9(9):762-773. doi: 10.1039/c7ib00091j.

PMID:
28752870
35.

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.

Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Cancer Sci. 2017 Sep;108(9):1843-1849. doi: 10.1111/cas.13309. Epub 2017 Jul 26.

36.

cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.

Miyano K, Cabral H, Miura Y, Matsumoto Y, Mochida Y, Kinoh H, Iwata C, Nagano O, Saya H, Nishiyama N, Kataoka K, Yamasoba T.

J Control Release. 2017 Sep 10;261:275-286. doi: 10.1016/j.jconrel.2017.06.021. Epub 2017 Jun 27.

PMID:
28666729
37.

Calcitriol exerts an anti-tumor effect in osteosarcoma by inducing the endoplasmic reticulum stress response.

Shimizu T, Kamel WA, Yamaguchi-Iwai S, Fukuchi Y, Muto A, Saya H.

Cancer Sci. 2017 Sep;108(9):1793-1802. doi: 10.1111/cas.13304. Epub 2017 Jul 16.

38.

ZEB1 expression is a potential indicator of invasive endometriosis.

Furuya M, Masuda H, Hara K, Uchida H, Sato K, Sato S, Asada H, Maruyama T, Yoshimura Y, Katabuchi H, Tanaka M, Saya H.

Acta Obstet Gynecol Scand. 2017 Sep;96(9):1128-1135. doi: 10.1111/aogs.13179. Epub 2017 Jul 7.

PMID:
28597474
39.

The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.

Tayama S, Motohara T, Narantuya D, Li C, Fujimoto K, Sakaguchi I, Tashiro H, Saya H, Nagano O, Katabuchi H.

Oncotarget. 2017 Jul 4;8(27):44312-44325. doi: 10.18632/oncotarget.17871.

40.

Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers necrosis of B-precursor leukemia cells with high surface CD44 expression.

Kasai S, Furuichi Y, Ando N, Kagami K, Abe M, Nakane T, Goi K, Inukai T, Saitoh S, Ohno S, Okazaki S, Nagano O, Saya H, Sugita K.

Cell Death Dis. 2017 Jun 1;8(6):e2857. doi: 10.1038/cddis.2017.249.

41.

Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells.

Kikuchi R, Sampetrean O, Saya H, Yoshida K, Toda M.

J Neurooncol. 2017 Jun;133(2):297-307. doi: 10.1007/s11060-017-2457-1. Epub 2017 May 29.

PMID:
28555424
42.

Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407).

Shitara K, Doi T, Nagano O, Fukutani M, Hasegawa H, Nomura S, Sato A, Kuwata T, Asai K, Einaga Y, Tsuchihashi K, Suina K, Maeda Y, Saya H, Ohtsu A.

Gastric Cancer. 2017 Nov;20(6):1004-1009. doi: 10.1007/s10120-017-0720-y. Epub 2017 May 2.

PMID:
28466360
43.

Distinct metaplastic and inflammatory phenotypes in autoimmune and adenocarcinoma-associated chronic atrophic gastritis.

Jeong S, Choi E, Petersen CP, Roland JT, Federico A, Ippolito R, D'Armiento FP, Nardone G, Nagano O, Saya H, Romano M, Goldenring JR.

United European Gastroenterol J. 2017 Feb;5(1):37-44. doi: 10.1177/2050640616644142. Epub 2016 Jun 23.

44.

Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells.

Ishimoto T, Miyake K, Nandi T, Yashiro M, Onishi N, Huang KK, Lin SJ, Kalpana R, Tay ST, Suzuki Y, Cho BC, Kuroda D, Arima K, Izumi D, Iwatsuki M, Baba Y, Oki E, Watanabe M, Saya H, Hirakawa K, Baba H, Tan P.

Gastroenterology. 2017 Jul;153(1):191-204.e16. doi: 10.1053/j.gastro.2017.03.046. Epub 2017 Apr 5.

PMID:
28390866
45.

Blocking COX-2 induces apoptosis and inhibits cell proliferation via the Akt/survivin- and Akt/ID3 pathway in low-grade-glioma.

Sato A, Mizobuchi Y, Nakajima K, Shono K, Fujihara T, Kageji T, Kitazato K, Matsuzaki K, Mure H, Kuwayama K, Sumi A, Saya H, Sampetrean O, Nagahirao S.

J Neurooncol. 2017 Apr;132(2):231-238. doi: 10.1007/s11060-017-2380-5. Epub 2017 Mar 10.

PMID:
28283800
46.

RNA Sequencing Analysis Reveals Interactions between Breast Cancer or Melanoma Cells and the Tissue Microenvironment during Brain Metastasis.

Sato R, Nakano T, Hosonaga M, Sampetrean O, Harigai R, Sasaki T, Koya I, Okano H, Kudoh J, Saya H, Arima Y.

Biomed Res Int. 2017;2017:8032910. doi: 10.1155/2017/8032910. Epub 2017 Jan 22.

47.

Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma.

Chew SH, Okazaki Y, Akatsuka S, Wang S, Jiang L, Ohara Y, Ito F, Saya H, Sekido Y, Toyokuni S.

Free Radic Biol Med. 2017 May;106:91-99. doi: 10.1016/j.freeradbiomed.2017.02.011. Epub 2017 Feb 6.

PMID:
28185919
48.

FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia.

Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton CB, Zhao R, Chachad D, Hashimoto N, Jacamo RO, Qiu Y, Yoo SY, Okamoto S, Andreeff M, Kornblau SM, Saya H.

Blood. 2017 Apr 6;129(14):1958-1968. doi: 10.1182/blood-2016-07-726216. Epub 2017 Jan 31.

49.

Development of Highly Selective Fluorescent Probe Enabling Flow-Cytometric Isolation of ALDH3A1-Positive Viable Cells.

Yagishita A, Ueno T, Esumi H, Saya H, Kaneko K, Tsuchihara K, Urano Y.

Bioconjug Chem. 2017 Feb 15;28(2):302-306. doi: 10.1021/acs.bioconjchem.6b00618. Epub 2016 Dec 15.

PMID:
27976863
50.

Simvastatin-Induced Apoptosis in Osteosarcoma Cells: A Key Role of RhoA-AMPK/p38 MAPK Signaling in Antitumor Activity.

Kamel WA, Sugihara E, Nobusue H, Yamaguchi-Iwai S, Onishi N, Maki K, Fukuchi Y, Matsuo K, Muto A, Saya H, Shimizu T.

Mol Cancer Ther. 2017 Jan;16(1):182-192. doi: 10.1158/1535-7163.MCT-16-0499. Epub 2016 Oct 31.

Supplemental Content

Support Center